[go: up one dir, main page]

FI3687576T3 - Kannabidiolin käyttö yhdessä norfenfluramiinin tai fenfluramiinin kanssa epilepsian hoidossa - Google Patents

Kannabidiolin käyttö yhdessä norfenfluramiinin tai fenfluramiinin kanssa epilepsian hoidossa

Info

Publication number
FI3687576T3
FI3687576T3 FIEP18782178.0T FI18782178T FI3687576T3 FI 3687576 T3 FI3687576 T3 FI 3687576T3 FI 18782178 T FI18782178 T FI 18782178T FI 3687576 T3 FI3687576 T3 FI 3687576T3
Authority
FI
Finland
Prior art keywords
amphetamine
cbd
receptor agonist
combination
cannabidiol
Prior art date
Application number
FIEP18782178.0T
Other languages
English (en)
Inventor
Benjamin Whalley
Geoffrey Guy
Volker Knappertz
Royston Gray
Rohini Rana
Original Assignee
Jazz Pharmaceuticals Res Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Res Uk Limited filed Critical Jazz Pharmaceuticals Res Uk Limited
Application granted granted Critical
Publication of FI3687576T3 publication Critical patent/FI3687576T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (11)

PATENTTIVAATIMUKSET
1. Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi epilepsian hoidossa, jolloin 5- HT2g-reseptoriagonisti, amfetamiini tai amfetamiinijohdannainen on — norfenfluramiini tai fenfluramiini, ja jolloin CBD:n suhde 5-HT2g- reseptoriagonistiin, amfetamiiniin tai amfetamiinijohdannaiseen on 1:2 tai noin
1:1.
2. CBD yhdessä 5-HT2g-reseptoriagonistin, amfetamiinin tai —amfetamiinijohdannaisen kanssa käytettäväksi patenttivaatimuksen 1 mukaisesti, jolloin yhdistelmä on tarkoitettu käytettäväksi 5-HT2e-reseptorin agonismiin liittyvien sivuvaikutusten ehkäisyyn tai vähentämiseen, jolloin ehkäistävä tai vähennettävä sivuvaikutus on sydänläppäsairaus.
3. Kannabidioli (CBD) yhdessä 5-HT2g-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin CBD on erittäin puhdistetun kannabisuutteen muodossa, joka sisältää CBD:tä vähintään 98 % (paino/paino).
4. Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi patenttivaatimuksen 1 tai 2 mukaisesti, jolloin CBD on synteettisenä yhdisteenä.
5. —Kannabidioli (CBD) yhdessä 5-HT2g-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin epilepsia on hoitoresistentti epilepsia (TRE).
6. —Kannabidioli (CBD) yhdessä 5-HT2g-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi patenttivaatimuksen 5 mukaisesti, jolloin hoitoresistentti epilepsia on yksi seuraavista: Dravet Syndrome; Myoclonic-Absence Epilepsy; Lennox-Gastaut-oireyhtymä; tuntemattomasta syystä johtuva Generalized Epilepsy; CDKL5-mutaatio; Aicardi-oireyhtymä; tuberoosi skleroosikompleksi; bilateraalinen polymikrogyria; Dup15g; SNAP25; ja kuumeiseen infektioon liittyvä epilepsiaoireyhtymä (FIRES); hyvänlaatuinen rolandinen epilepsia; nuoruusiän myokloninen epilepsia; infantiili spasmi (West syndrome); ja Landau-Kleffner-oireyhtymä.
7. Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi patenttivaatimuksen 3 mukaisestti, jolloin erittäin puhdistettu uute sisältää THC:tä alle 0,15 %.
8. —Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen käytettäväksi patenttivaatimuksen 3 mukaisesti, jolloin erittäin puhdistettu uute sisältää CBDV:tä enintään 1 %.
9. Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin CBD:n suhde 5-HT2s-reseptoriagonistiin, amfetamiiniin tai amfetamiinijohdannaiseen on 1:2.
10. Kannabidioli (CBD) yhdessä 5-HT2e-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin CBD:n suhde 5-HT2s-reseptoriagonistiin, amfetamiiniin tai amfetamiinijohdannaiseen on noin 1:1.
11. Kannabidioli (CBD) yhdessä 5-HT2s-reseptoriagonistin, amfetamiinin tai amfetamiinijohdannaisen kanssa käytettäväksi jonkin edellisen patenttivaatimuksen mukaisesti, jolloin CBD:n annos on 5-50 mg/kg/vrk.
FIEP18782178.0T 2017-09-29 2018-10-01 Kannabidiolin käyttö yhdessä norfenfluramiinin tai fenfluramiinin kanssa epilepsian hoidossa FI3687576T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1715919.5A GB201715919D0 (en) 2017-09-29 2017-09-29 use of cannabinoids in the treatment of epilepsy
GBGB1806481.6A GB201806481D0 (en) 2017-09-29 2018-04-20 Use of cannabinoids in the treatment of epilepsy
PCT/GB2018/052805 WO2019064031A1 (en) 2017-09-29 2018-10-01 USE OF CANNABIDIOL IN COMBINATION WITH 5-HT2B RECEPTOR AGONISTS OR AMPHETAMINES IN THE TREATMENT OF EPILEPSY

Publications (1)

Publication Number Publication Date
FI3687576T3 true FI3687576T3 (fi) 2025-10-12

Family

ID=60270232

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18782178.0T FI3687576T3 (fi) 2017-09-29 2018-10-01 Kannabidiolin käyttö yhdessä norfenfluramiinin tai fenfluramiinin kanssa epilepsian hoidossa

Country Status (16)

Country Link
US (1) US11419829B2 (fi)
EP (1) EP3687576B1 (fi)
JP (1) JP7359757B2 (fi)
KR (1) KR102739080B1 (fi)
CN (1) CN111201039B (fi)
AU (1) AU2018341091B2 (fi)
BR (1) BR112020006105A2 (fi)
CA (1) CA3076995A1 (fi)
DK (1) DK3687576T3 (fi)
ES (1) ES3041966T3 (fi)
FI (1) FI3687576T3 (fi)
GB (3) GB201715919D0 (fi)
IL (1) IL273583B2 (fi)
MX (1) MX2020003934A (fi)
RU (1) RU2020114753A (fi)
WO (1) WO2019064031A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US12083116B2 (en) * 2018-06-21 2024-09-10 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
JP2021530541A (ja) * 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
AU2019384963B2 (en) * 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
US12398093B2 (en) 2019-04-12 2025-08-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds and methods for treating inflammatory disorders
GB2584140A (en) * 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
WO2021072530A1 (en) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CA3182156A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
GB2597316A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
CN114196645B (zh) * 2021-09-10 2022-08-09 北京蓝晶微生物科技有限公司 一种橄榄醇合成酶变体l及其用途
WO2023168022A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocybin
CN118873517A (zh) * 2024-07-05 2024-11-01 上海柯西医药科技发展有限公司 大麻二酚与5-ht2b受体激动剂的组合的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428444A1 (de) * 1994-08-11 1996-02-15 Dresden Arzneimittel Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
PT3340971T (pt) 2015-08-24 2024-06-05 Zogenix International Ltd Métodos de tratamento da síndrome de lennox-gastaut com utilização de fenfluramina
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
CA3032996C (en) * 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
BR112019023483A2 (pt) * 2017-05-09 2020-06-30 Zogenix International Limited composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
GB201806481D0 (en) 2018-06-06
AU2018341091B2 (en) 2024-09-26
IL273583A (en) 2020-05-31
IL273583B1 (en) 2025-01-01
US20200237683A1 (en) 2020-07-30
ES3041966T3 (en) 2025-11-17
JP2020535198A (ja) 2020-12-03
US11419829B2 (en) 2022-08-23
CA3076995A1 (en) 2019-04-04
CN111201039B (zh) 2022-11-22
EP3687576B1 (en) 2025-09-03
GB201715919D0 (en) 2017-11-15
JP7359757B2 (ja) 2023-10-11
RU2020114753A3 (fi) 2021-10-29
GB2568809B (en) 2022-04-27
CN111201039A (zh) 2020-05-26
IL273583B2 (en) 2025-05-01
KR102739080B1 (ko) 2024-12-04
KR20200060422A (ko) 2020-05-29
MX2020003934A (es) 2020-10-12
EP3687576A1 (en) 2020-08-05
BR112020006105A2 (pt) 2020-09-29
GB2568809A (en) 2019-05-29
WO2019064031A1 (en) 2019-04-04
DK3687576T3 (da) 2025-09-29
RU2020114753A (ru) 2021-10-29
AU2018341091A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
FI3687576T3 (fi) Kannabidiolin käyttö yhdessä norfenfluramiinin tai fenfluramiinin kanssa epilepsian hoidossa
FI3743053T3 (fi) Kannabinoidien käyttö epilepsian hoidossa
KR102786614B1 (ko) 레녹스-가스토 증후군 관련 발작의 치료에서 칸나비노이드의 용도
FI3641819T3 (fi) Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon
MX2021014158A (es) Uso de cannabidiol en el tratamiento de espasmos epilepticos.
MX2021003331A (es) Uso de cannabinoides en el tratamiento de epilepsia.
RU2020121661A (ru) Применение каннабиноидов при лечении эпилепсии
MX387442B (es) Composiciones y tratamientos para el trastorno del sueño
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
NO20091260L (no) Kombinasjonsbehandling for diabetes mellitus
PH12015501425A1 (en) Method of treatment using lactobacillus fermentum me-3
PH12015501474B1 (en) Compositions containing chondroitin sulphate, proteolytic enzymes and sulphydryl compounds for improving the bioavailability of chondroitin sulphate
MX2023008447A (es) Composiciones y metodos para prevenir, mejorar o reducir enfermedades inducidas por radiacion.
DeBattista et al. Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
WO2005086754A3 (en) Dicationic compounds for activity against trichomonas vaginalis
PH12021550215A1 (en) Composition comprising isomers of inositol and its use
WO2011093742A8 (ru) Средство для лечения болезни паркинсона
WO2011163231A3 (en) Combination therapy for the treatment of diabetes
WO2010065524A3 (en) Methods and compositions for the treatment of fluid retention disorders
Brandenburg et al. COMPARISON OF TWO BLUEBERRY SUPPLEMENTATION PROTOCOLS ON RUNNING PERFORMANCE AND PHYSIOLOGICAL RESPONSES
WO2007019065A3 (en) Adjuvant chemotherapy for anaplastic gliomas
CA3247785A1 (en) USE OF 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT DISEASES ASSOCIATED WITH SUDDEN UNSURPRISED DEATH IN EPILEPSY
Sidana et al. Episodic obsessive compulsive disorder: a case report
Watanabe Acute generalised exanthematous pustulosis in children: 2 case reports